Navigation Links
New cell therapy a promising atherosclerosis treatment
Date:3/1/2011

Researchers at Karolinska Institutet have shown in a new study on mice, that cell therapy can be used to reverse the effect of 'bad' LDL cholesterol and reduce the inflammation that leads to atherosclerosis. The new cell therapy, which is presented in the prestigious scientific journal Circulation, can open the way for new therapies for stroke and myocardial infarction if the results prove translatable to humans.

Atherosclerosis is a chronic inflammation of the blood vessels. Cholesterol is transported in the blood in particles called LDL ('bad' cholesterol) that can accumulate in the vessel walls. This triggers the body's immune system to react against LDL, which then cause inflammation in the vessels, and eventually thrombus formation. If such a thrombus forms in the coronary artery, the patient suffers a myocardial infarction; if it forms in the brain, a stroke can result.

The research group, under the direction of Professor Gran K Hansson at the Centre for Molecular Medicine, have developed a cell therapy that selectively dampens vascular inflammation induced by LDL. The therapy makes use of dendritic cells, which are characterized by a high degree of plasticity that renders them amenable to manipulation.

"With the appropriate treatment, dendritic cells can be made to inhibit rather than aggravate the inflammation around the LDL particles in the blood vessels," says Dr Andreas Hermansson, one of the researchers conducting the study. "A major advantage of this is that we can devise a treatment for vascular diseases that is highly specific."

The mouse studies now presented in Circulation have demonstrated substantial protective effects of the treatment, with a reduction of the atherosclerosis process of up around 70 percent. Last year, the researchers published results showing that antibodies recognizing the receptors that drive the immune reaction have protective effects, and now the same group is presenting a cell therapy that is at least as efficacious. It is hoped that this will pave the way for a completely new generation of selective anti-inflammatory therapies for cardiovascular disease.

"Treatments of atherosclerosis have traditionally targeted blood lipids, but a large proportion of treated patients still suffer life-threatening infarctions and stroke," says Professor Hansson. "We're now looking at the possibility of getting to the root of the problem and re-set, so to speak, the immune system's reaction to LDL, since it often has devastating consequences."


'/>"/>

Contact: Katarina Sternudd
katarina.sternudd@ki.se
46-852-483-895
Karolinska Institutet
Source:Eurekalert

Related biology news :

1. Why chemotherapy causes more infertility in women than in men
2. First-of-its-kind study shows benefits of electrical stimulation therapy for people paralyzed by spinal cord injury
3. Drug therapy shows significant benefit in treating a leading cause of childhood blindness
4. U of Alberta researcher discovers potential cancer therapy target
5. UTHealth, Athersys preclinical research on stem cell therapy for stroke presented at AHA conference
6. Photodynamic therapy against cancer
7. A loose grip provides better chemotherapy
8. Early tests find nanoshell therapy effective against brain cancer
9. New anti-HIV gene therapy makes T-cells resistant to HIV infection
10. Caffeine energizes cells, boosting virus production for gene therapy applications
11. Nanodisk gene therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... 5, 2017  Delta ID Inc., a leader in ... for automotive at CESĀ® 2017. Delta ID has collaborated ... demonstrate the use of iris scanning as a secure, ... driver in a car, and as a way to ... Delta ID and Gentex will demonstrate (booth ...
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ), ... HealthCare, and Finance sectors announced today that Leaders in Community Alternatives ... deploy a community-based supportive services program to reduce recidivism in a ... its presence in the state. ... This new program, which is expected to commence in ...
(Date:12/16/2016)... Research and Markets has announced the addition of the ... report to their offering. ... The biometric vehicle access system market, in terms of ... 2016 to 2021. The market is estimated to be USD 442.7 ... 2021. The growth of the biometric vehicle access system market is ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... 2017 /PRNewswire -- WuXi AppTec, a leading global ... technology platform, today announced that it has acquired ... drug discovery contract research organization (CRO). After completion ... subsidiary of WuXi, and will continue to focus ... services. The acquisition will further strengthen WuXi,s R&D ...
(Date:1/19/2017)... 19, 2017  ArmaGen, Inc., today announced that ... as chief executive officer, as well as a ... to ArmaGen more than 17 years of executive ... of biotherapeutics and pharmaceuticals. "Mathias ... experience and skillset necessary to lead ArmaGen to ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical Research ... drug and device development, and Prism Clinical Research , a leader in ... Verified Clinical Trials (VCT) has been selected by both companies as ...
(Date:1/18/2017)... ... January 18, 2017 , ... Opal Kelly, ... USB or PCI Express, announced the ZEM5310 USB 3.0 FPGA Module, combining a ... compact business-card sized form factor suitable for prototyping, testing, and production-ready integration. The ...
Breaking Biology Technology: